UBT251

UBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist

N/A Amino Acids · MW: N/A

Ask AI About This

Amino Acids

N/A

Molecular Weight

N/A

Half-life

Approximately 1 week

Research Score

4.0

Studies

Storage

Store lyophilized at -20°C, reconstituted at 2-8°C

What is UBT251?

UBT251 is a research-stage triagonist that targets GLP-1, GIP, and glucagon receptors for body-weight reduction and metabolic improvement. It represents a newer class of multi-receptor incretin compounds under active investigation.

Key Benefits & Mechanisms

weight reduction

improved satiety

enhanced energy expenditure

better insulin sensitivity

Research Summary

Published work supports strong anti-obesity activity in preclinical models, with translation into human studies still emerging. The compound remains investigational and is best characterized as an early multi-agonist program.

Related Peptides

Oxyntomodulin

Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide

Oxyntomodulin is a naturally occurring proglucagon-derived peptide that activates GLP-1 and glucagon pathways. It is a key research tool for appetite suppression and energy balance studies in obesity.

Weight Management

Cotadutide

MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist

Cotadutide is a synthetic oxyntomodulin analogue designed to engage both GLP-1 and glucagon receptors. It was developed to improve weight loss and metabolic markers in obesity and type 2 diabetes research.

Weight Management

Mazdutide

IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist

Mazdutide is a long-acting oxyntomodulin-inspired dual agonist being developed for obesity and metabolic disease. It is designed to drive clinically meaningful weight loss while improving glucose and lipid parameters.

Weight Management

Dulaglutide

Recombinant GLP-1 receptor agonist Fc fusion protein

Dulaglutide is a long-acting GLP-1 receptor agonist used primarily in type 2 diabetes. It consistently produces modest weight loss and is widely studied as a benchmark incretin mimetic.

Weight Management